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Abstract
Background: Inappropriate medical treatment of co-morbidities in Alzheimer’s disease (AD) is an increasing
concern in geriatric medicine. The objective of this study was to compare current drug use related to co-morbidity
between individuals with a recent diagnosis of AD and a cognitively healthy control group in a population based
clinical trial in Northern Norway.
Methods: Setting: Nine rural municipalities with 70 000 inhabitants in Northern Norway.
Participants: Participants with and without AD recruited in general practice and by population based screening.
187 participants with a recent diagnosis of AD were recruited among community dwellers. Of 791 respondents
without cognitive symptoms, 500 were randomly selected and invited to further clinical and cognitive testing. The
final control group consisted of 200 cognitively healthy individuals from the same municipalities. Demographic
characteristics, data on medical history and current medication were included, and a physical and cognitive
examination was performed. The statistical analyses were carried out by independent sample t-test, chi-square,
ANCOVA and logistic regression.
Results: A co-morbidity score was significantly higher in AD participants compared to controls. The mean number
of drugs was higher for AD participants compared to controls (5.1 ± 3.6 and 2.9 ± 2.4 respectively, p < 0.001 age
and gender adjusted), also when adjusted for co-morbidity. AD participants used significantly more anticholinergic,
sedative and antidepressant drugs. For nursing home residents with AD the mean number of drugs was
significantly higher compared to AD participants living at home (6.9 ± 3.9 and 4.5 ± 3.3, respectively, p < 0.001).
Conclusions: AD participants were treated with a significantly higher number of drugs as compared to cognitively
healthy controls, even after adjustment for co-morbidity. An inappropriate use of anticholinergic and sedative
drugs was identified, especially among nursing home residents with AD. The drug burden and the increased risk of
adverse reactions among individuals suffering from AD need more attention from prescribing doctors.
Background
The proportion of elderly with age-related diseases is
rapidly increasing worldwide representing a vulnerable
population with respect to medication issues. In particu-
lar, this is true for Alzheimer’s disease (AD), constitut-
ing 65 - 70% of all dementia subtypes, inflicting an
extensive and serious impact on activities of daily living
and quality of life for patients and their caregivers [1-5].
The prevalence of AD increases by age [6-8] as does a
number of other age related disorders.
Individuals suffering from AD often have cardiovascu-
lar diseases such as coronary heart disease, stroke, dia-
betes mellitus and hypertension, requiring use of
multiple drugs. Schubert et al. reported that patients
with dementia attending primary care have on average
2.4 chronic conditions and receive 5.1 medications [9].
Likewise, psychiatric disorders like depression and sleep-
ing disturbances are prevalent. Twenty-five to 35% of
AD individuals have sleep disturbances being treated
with hypnotics [10]. Particularly, anxiolytic-hypnotic
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agents, antidepressants and antihistamines that often
exhibit central nervous system effects are associated
with increased cognitive impairment, sedation and con-
fusion. Consequently, multiple drug prescriptions are
leaving elderly vulnerable to adverse reactions [10-12]
and harmful interactions between psychotropic drugs
and between psychotropic drugs and drugs aimed to
treat co-morbidities, often classified as inappropriate
drug prescriptions [13].
Despite the heavy drug load elderly are exposed to,
few studies have examined overall medication in demen-
tia [12], and even fewer studies have focused on appro-
priate medical treatment of co-morbidity in AD patients
[14,15].
The main purpose of this paper is to compare drug
treatment in relation to co-morbidity, focusing on inap-
propriate prescriptions between individuals with a recent
diagnose of AD and a randomly selected cognitively
healthy control group.
Methods
Participants
From January 2006 to March 2008 187 participants with
a recent diagnosis of a probable AD were included in
The Dementia Study in Northern Norway, run in nine
rural municipalities with 70000 inhabitants (11807 indi-
viduals > = 65 year). Forty-five AD participants were
nursing home residents. The two different recruitment
methods which were used and the baseline characteris-
tics comparing the two samples are described in an ear-
lier paper [16]. AD participants were recruited by
general practitioners (n = 87) and by a population based
screening (n = 100). The latter method also recruited a
cognitively healthy control group (n = 200) (Figure 1).
The present study is a cross sectional comparison
between AD participants in a randomised controlled
trial and a cognitively healthy control group.
Clinical examination
All AD participants and the cognitively healthy controls
passed the same examinations performed by trained
physicians and nurses. Dementia and AD were diag-
nosed by GPs and geriatric specialists using the ICD-10
[17] criteria and the Statistical Manual of Mental Disor-
ders fourth edition (DSM-IV-TR) [18]. Diagnostic dis-
crepancies were discussed with a geriatric colleague and
solved by consensus advised by National Institute of
Neurological Disorders and Stroke-Alzheimer Disease
and Related Disorders (NINCDS-ADRDA) [19] criteria
for probable AD. A third specialist (MV) was consulted
if disagreement continued. Blood pressure was mea-
sured automatically by DINAMAP ProCare [20]. Three
consecutive blood pressures were recorded and the
mean of the second and the third measures was used to
calculate mean arterial blood pressure (MAP). Body
mass index (BMI) was calculated. A 12 channels elec-
trocardiogram (ECG) was registered. Cognition was
tested at entry by Mini-Mental-State-Examination
(MMSE) [21] and Clock drawing test [22]. Prior to the
study onset two test technicians were trained at the
Geriatric Department, University Hospital in Northern
Norway. To improve intra- and inter-rater reliability
they observed and evaluated each other by testing a
number of patients with MMSE, Alzheimer’s disease
Assessment Scale, cognitive (ADAS-Cog) [23] and Neu-
ropsychiatric Inventory (NPI) [24].
Medical history
The demographic characteristics and self-reported medi-
cal history were registered in a questionnaire regarding
the most common life style and age related illnesses like
cardiovascular diseases (i.e. myocardial infarct, angina
pectoris, congestive heart failure, atrial fibrillation),
hypertension, stroke, diabetes, chronic pain and neurop-
sychiatric complains. A co-morbidity score was calcu-
lated for each participant by adding the number of age
related diseases identified as AD risk factors [25,26] pro-
viding a sum score of chronic health conditions [9]. The
physicians had access to the medical record of AD parti-
cipants confirming given information. In addition the
caregiver or a next of kin was encouraged to extend the
medical history. Computerised ECG assessed by an
experienced physician validated a medical history of cor-
onary heart disease.
Drug treatment
Drugs used at study entry by AD participants and con-
trols were registered and daily medication was checked
according to medication charts, information given by
caregiver(s) and the medical record. The medication
charts were also checked against reported co-morbid-
ities. Drugs were classified and recorded according to
the Anatomic Therapeutic Classification system (ATC
codes) [27] like anxiolytic-hypnotics (N05B and C) anti-
depressants (N06A), antipsychotics (N05A), lipid lower-
ing agents (C10A), antihypertensive drugs (C09A, B, C
and D, C08C and D, C07A and B, C03A, C, D and E)
and a heterogeneous group consisting of drugs with
anticholinergic activities. According to the Anticholiner-
gic Drug Scale [28] drugs with anticholinergic activity
are grouped into four levels (level 0 - 3) [28-30]. In this
study drugs exhibiting a significant or a moderate level
of anticholinergic effect (level 2 and 3) were recorded.
Inappropriate drugs were classified according to the
Screening Tool of Older Persons’ Prescription (STOPP)
criteria which comprise a list of drugs at risk of interac-
tion and adverse reactions when combined with com-
mon illnesses in geriatric practice [13].
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Approvals
The Dementia study in Northern Norway complies with
the Norwegian Research Legislation and the Helsinki
Declaration, and the present manuscript complies with
the CONSORT statement. The Regional Committee for
Medical Research Ethics in Northern Norway, The Priv-
acy Ombudsman for Research, The Directory of Health
and Social Welfare and The Norwegian Medicine
Agency including registration in the EudraCT database
(no 2004-002613-37) approved the study. Each AD par-
ticipant gave a written informed consent co-signed by a
next of kin or a caregiver whereas participants in the
cognitively healthy control group gave a written
informed consent on their own. The present manuscript
is based on data already collected in The Dementia
Study in Northern Norway.
Statistics
Statistical analyses were carried out using SPSS version
18.0 (SPSS Inc. Chicago, US). Differences in age, gender,
heredity, co-morbidity and current drug use between
participants with and without AD were analyzed by
independent sample t-tests and Chi-Square tests.
Adjustment for age, gender and co-morbidity score were
done by covariance analyses and logistic regression. A
two-sided 5% significance level was used. The results are
presented both unadjusted and age and gender adjusted.
The calculation of 95% confidence interval (CI) refers to
age and gender adjusted differences between samples or
groups according to the ANCOVA or to logistic regres-
sion analyses.
Result
Baseline characteristics
AD participants were older (p < 0.001), more often
female (p < .0.001) and reported dementia among close
relatives (p < 0.001) more frequently compared to con-
trols. Mean arterial blood pressure was significantly
lower among AD participants compared to controls (p =
0.009 age and gender adjusted) (Table 1).
Medical history
The co-morbidity score was higher in AD participants
compared to controls (2.1 ± 1.5 and 1.3 ± 1.2 respec-
tively, p < 0.001). AD participants had a higher fre-
quency of cardiovascular diseases (i.e. angina pectoris,
myocardial infarct, congestive heart failure and atrial
fibrillation), stroke, diabetes mellitus, hypertension,
chronic obstructive bronchitis and chronic pain but sig-
nificantly for chronic obstructive bronchitis only
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Population based 
screening by mail 
n=11807 
Responders n (%) 
3767 (31.3) 
AD participants included after 
screening and examination 
n=100 
Answered NO to all questions 
concerning cognitive impairment and 
YES to the question of participation 
n=791 
Randomisation 
Invited to participate in 
the control group 
n=500 Confirmed cognitively 
healthy and included 
in the control group 
n=200 
AD participants 
recruited by GPs 
and included 
n=87 
All AD participants 
included in the study 
n=187 
Figure 1 Flowchart revealing recruitment methods and participants.
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(adjusted for age and gender) (Table 2). The differences
in mean number of co-morbidities were non-significant
between AD participants recruited by screening or by
GPs (2.3 ± 1.5 and 2.0 ± 1.6 respectively, p = 0.20) and
between AD participants living at home or in nursing
homes (2.4 ± 1.6 and 2.1 ± 1.5 respectively, p = 0.20).
(Data not shown)
Drug treatment
The mean number of drugs was significantly higher in
AD participants compared to controls (5.1 ± 3.6 and 2.9
± 2.4 respectively, age and gender adjusted difference of
means 1.48, 95%CI 0.78 to 2.21, p < 0.001). This finding
remained unchanged when adjusting for co-morbidity
score (p < 0.001). Forty-eight percent of AD participants
used five or more drugs compared to 23% in the control
group (95%CI for age and gender adjusted differences
0.076 to 0.298, p = 0.001) (Table 3). AD participants used
a greater number of antihypertensive drugs. Inappropri-
ate drugs such as anticholinergics, antidepressants and
anxiolytic/hypnotics were prescribed more frequently to
AD participants compared to controls (Table 3).
The total number of prescribed drugs was significantly
higher among nursing home residents with AD (n = 45)
compared to AD participants living at home (6.9 ± 3.9
and 4.5 ± 3.3 respectively, age and gender adjusted dif-
ferences of means -2.07, 95%CI -3.30 to -0.83, p =
0.001). Nursing home residents with AD used signifi-
cantly more antidepressants (13 of 45 and 11 of 142
respectively, p < 0.001) and anxiolytic-hypnotics (18 of
45 and 23 of 141, p < 0.001) compared to AD partici-
pants living at home. No significant differences in num-
ber of drugs was detected between AD participants
when MMSE score was grouped as a dichotomized vari-
able (= < 21 or > 21) (5.8 ± 4.2 versus 4.8 ± 3.2 respec-
tively, p = 0.16, age and gender adjusted) or between
Table 1 Baseline characteristics of AD participants
compared to controls
AD
n = 187
Control
n = 200
p-value
Age (years ± SD)
80.9 ± 7.0 72.5 ± 5.5 < 0.001
Gender, women
n (%) 113 (60) 85 (43) < 0.001
Familiar disposition
n (%) 56 (31) 29 (15) < 0.001
Education ≥ 10 years
n (%) 33 (17) 126 (63) 0.33*
MMSE score ± SD
23.1 ± 4.5 28.7 ± 1.6 < 0.001*
MAP ± SD
100.9 ± 16.6 107.2 ± 13.6 0.009*
BMI ± SD
25.4 ± 5.0 26.0 ± 4.2 0.59*
*Age and gender adjusted. MAP = Mean arterial blood pressure. BMI = Body
mass index. SD = standard deviation
Table 2 Co-morbidities AD participants compared to controls
AD participants
n = 187
Controls n = 200 Unadjusted
p-value
Adjusted p-value*
Co-morbidity score
2.1 ± 1.5 1.3 ± 1.2 < 0.001 < 0.001
Cardiovascular diseases**
n (%) 139 (74) 114 (57) < 0.001 0.14
Angina pectoris
n (%) 48 (26) 18 (9) < 0.001 0.37
Myocardial infarct
n (%) 27 (14) 24 (12) 0.52 0.26
Atrial fibrillation
n (%) 34 (18) 18 (9) 0.008 0.40
Stroke
n (%) 33 (18) 11 (6) < 0.001 0.82
Hypertension
n (%) 102 (55) 82 (41) 0.008 0.14
Diabetes mellitus
n (%) 21 (11) 17 (9) 0.37 0.15
Chronic obstructive bronchitis
n (%) 19 (10) 10 (5) 0.054 0.003
Chronic pain
n (%) 47 (25) 41 (21) 0.28 0.17
* Adjusted for age and gender. ** Participants suffering from one or more of congestive heart failure, angina pectoris, myocardial infarct, angina pectoris or atrial
fibrillation.
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AD participants recruited by screening or by GPs (5.0 ±
3.5 versus 5.2 ± 3.7 respectively, p = 0.56 age and gen-
der adjusted) (Data not shown).
Discussion
Medical history
The co-morbidity score was significantly higher in AD
participants compared to controls but turned out non-
significant for nine of ten recorded co-morbidities when
adjusting for age and gender. This is in line with other
studies[9,31,32] whereas one study using a historical
cohort of community dwellers with and without AD
reported a significant higher prevalence for 12 of 14
health conditions among AD individuals [33].
In our study, AD participants reported higher lifetime
occurrence of hypertension and were more often treated
with a greater number of antihypertensive drugs. Pre-
vious observations have shown that AD is associated
with elevated systolic blood pressure in midlife followed
by a greater decrease with aging compared to cognitively
healthy individuals [31,34]. Midlife hypertension may
generate arteriosclerosis, cerebral small-vessel disease
and disturbed cerebral autoregulation in resistant
arteries [35-37], leaving elderly AD individuals prone to
cerebral hypoperfusion and cognitive worsening due to
extensive antihypertensive treatment [38,39].
Drug treatment
In the present study AD participants consumed a signif-
icant higher number of drugs compared to controls,
similar to the results reported by Schubert et al [9].
Adjusting for co-morbidity score did not change the
results. Any prescription has a potential risk of adverse
reactions and the risk increases with the number of
drugs, from a 10% with one drug to 75% with five or
more drugs [40]. In our study 48% of the AD partici-
pants used five or more drugs compared to 23% of the
controls. The nursing home AD residents consumed a
mean of 6.9 ± 3.9 different drugs a day, quite similarly
to what Holmes et al reported [41].
Inappropriate medication is based on the STOPP cri-
teria [13], and in our study 37% of the AD participants
used one or more drugs considered inappropriate com-
pared to 11% in the control group (p < 0.001) (Table 3).
In a recent paper Barnett et al concluded that the high
prevalence of inappropriate drugs in older people con-
tinues to occur despite the recognition and concerns of
iatrogenic harms [42].
In the present study AD participants were significantly
more often treated with drugs with anticholinergic side
effects compared to controls (p < 0.001). Drugs with
anticholinergic properties are considered inappropriate
in elderly patients as a consequence of adverse reactions
including constipation, dry mouth, blurred vision and
dizziness which may contribute to falls and delirium
[43]. Increased levels of anticholinergic activity are asso-
ciated with increased cognitive decline assessed by
MMSE and even dementia [11,44-46]. Interruption of
the anticholinergic medication may represent a thera-
peutic option to improve cognitive performance [47],
Table 3 Current drug use in AD participants compared to controls
AD
n = 187
Control
n = 200
Difference* 95%CI* p-value*
Mean number of drugs ± SD
5.1 ± 3.6 2.9 ± 2.4 1.48 0.78 to 2.21 < 0.001
Mean number of antihypertensive drugs ± SD
1.4 ± 1.3 0.8 ± 0.9 0.28 0.012 to 0.538 0.040
Participants using five drugs or more
n(%) 90(48) 46(23) 0.19 0.076 to 0.289 0.001
antihypertensive drugs
n(%) 128(68) 101(50) 0.039 -0.074 to 0.153 0.50
anticholinergic drugs
n(%) 43(23) 12(6) 0.161 0.080 to 0.243 < 0.001
antidepressants
n(%) 24(13) 4(2) 0.091 0.030 to 0.151 0.004
anxiolytic-hypnotic drugs
n(%) 42 (22) 15(8) 0.090 0.008 to 0.172 0.032
inappropriate drugs**
n(%) 69(37) 22(11) 0.193 0.097 to 0.288 < 0.001
lipid lowering agents
n(%) 53(28) 69(35) 0.000 -0.111 to 0.112 0.99
SD = Standard deviation. CI = Confidence interval for age and gender adjusted differences. * Age and gender adjusted. Percentage differences in CIs are
expressed in fractions. **According to STOPP criteria for inappropriate drug treatment
Andersen et al. BMC Geriatrics 2011, 11:58
http://www.biomedcentral.com/1471-2318/11/58
Page 5 of 7
especially where anticholinergic drugs are give simulta-
neously with cholinesterase inhibitors.
In our study, anxiolytic-hypnotics and antidepressants
were used more frequently in the AD group compared
to the control group (p = 0.032). Among nursing home
AD residents 18 of 45 (40%) used anxiolytic-hypnotics.
In another study 20% of AD individuals in general prac-
tice were prescribed at least one psychotropic drug.
Anxiolytic-hypnotic drugs are known to influence alert-
ness, power of reaction, risk of falls and functional and
cognitive impairment [48].
Strengths and weaknesses
This study has a population-based design and is accom-
plished on a community level providing a homogenous
sample with minimal environmental influence. The parti-
cipants in this study were examined according to standar-
dized procedures and diagnoses were based on accepted
validated criteria and were confirmed by an expert panel.
A self-report of the medical history by AD participants
could be inaccurate and at risk of recall bias, but the
method is in accordance with several geriatric studies
based on self-reported chronic medical conditions [40].
A weakness of the study is that defined daily doses of
medication and the length of treatment have not been
recorded. The differences in mean age and gender distri-
bution between the AD group and the control group are
significant, but adjustment for age and gender was per-
formed in the statistical analyses. However, age and gen-
der adjustment is questionable when it comes to some
of the variables like familiar disposition and prevalence
of hypertension.
Conclusion
In the present study AD participants used more drugs
than cognitively healthy controls despite similar fre-
quency of co-morbidity. The AD participants had nearly
a two-fold use of drugs and inappropriate use of antic-
holinergic, anxiolytic-hypnotic and antidepressants were
detected. The drug burden and the increased risk of
adverse reactions among individuals suffering from AD
need more attention from prescribing doctors.
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